## Naloxone-Induced Acute Opioid Withdrawal ### Clinical Presentation The patient's acute onset of: - Agitation and anxiety - Tachycardia (HR 120/min) - Hypertension (BP 160/95 mmHg) - Severe pain (abdominal and back) ...within 2 minutes of naloxone administration is pathognomonic for **acute opioid withdrawal**. ### Mechanism of Withdrawal **Key Point:** Naloxone is a competitive opioid antagonist that rapidly displaces opioids from μ, δ, and κ receptors. In a patient who has received opioids intraoperatively and developed acute physical dependence, sudden receptor antagonism triggers withdrawal. **Mnemonic: SLUDGE (modified for opioid withdrawal)** — though opioid withdrawal does NOT cause cholinergic signs, it causes: - **S**weating, **A**gitation - **L**acrimation (tearing) - **U**reteral/urinary symptoms - **D**iarrhea - **G**astrointestinal cramping (abdominal pain) - **E**motional lability Additionally: mydriasis (dilated pupils), piloerection ("goosebumps"), yawning, insomnia, tachycardia, hypertension, muscle aches. ### Pathophysiology During opioid infusion, the locus coeruleus (noradrenergic nucleus) is suppressed by μ-receptor activation. Acute antagonism causes sudden disinhibition, leading to: 1. Massive noradrenergic discharge 2. Sympathetic hyperactivity (tachycardia, hypertension) 3. Hyperalgesia (heightened pain perception) 4. Emotional dysregulation (agitation) ### Risk Factors for Intraoperative Withdrawal | Factor | Mechanism | |--------|----------| | **High-dose or prolonged opioid infusion** | Greater degree of CNS adaptation and dependence | | **Rapid naloxone administration** | Abrupt receptor blockade without gradual tapering | | **Naloxone overdose** | Excessive antagonism increases symptom severity | | **Patient on chronic opioids** | Pre-existing physical dependence amplifies withdrawal | ### Management of Acute Withdrawal **High-Yield:** Once withdrawal is recognized: 1. **Reduce naloxone dose or withhold further doses** — the antagonist has already been given; additional doses will worsen symptoms 2. **Reinstitute opioid therapy** — small doses of morphine or fentanyl will rapidly reverse withdrawal symptoms 3. **Supportive care** — anxiolytics (benzodiazepines), analgesia, reassurance 4. **Titrate naloxone carefully** — if reversal is essential, use lower doses (0.1–0.2 mg) and titrate slowly **Clinical Pearl:** In the operating room, it is often safer to allow residual opioid effect (mild respiratory depression) to recover naturally rather than fully reverse with naloxone, especially in patients without contraindications to opioid-induced respiratory depression (e.g., those with adequate postoperative monitoring). ### Why Other Options Are Wrong | Option | Reason | |--------|--------| | **Anaphylactic reaction to naloxone** | Anaphylaxis presents with urticaria, angioedema, bronchospasm, hypotension, and cardiovascular collapse. The patient is hypertensive and has no respiratory distress or rash. | | **Inadequate neuromuscular blockade reversal** | Residual neuromuscular blockade causes weakness and inability to move, not agitation, tachycardia, or hypertension. | | **Emergence delirium from propofol** | Propofol emergence delirium is rare, occurs during emergence (not after naloxone), and is not accompanied by the acute sympathetic surge seen here. | ### Prevention Strategies - Use **lower doses of naloxone** (0.1–0.2 mg) and titrate to effect rather than full reversal - **Avoid naloxone reversal** in routine cases; allow natural recovery of opioid effect - If reversal is necessary, use **nalmefene** (longer-acting antagonist, ~8 hours) instead of naloxone to prevent rebound respiratory depression - In chronic opioid patients, consider **partial agonists** (buprenorphine) instead of full antagonists [cite:Harrison 21e Ch 394; Miller's Anesthesia 8e Ch 32]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.